Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DXUF4A
|
||||
Drug Name |
N-(benzo[d][1,3]dioxol-5-ylmethyl)-5-(1-methyl-4-(pyridin-4-ylmethylamino)-1H-imidazol-5-yl)-1,3,4-oxadiazol-2-amine
|
||||
Synonyms |
CHEMBL202892
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C20H19N7O3
|
||||
Canonical SMILES |
Cn1cnc(NCc2ccncc2)c1c3oc(NCc4ccc5OCOc5c4)nn3
|
||||
InChI |
InChI=1S/C20H19N7O3/c1-27-11-24-18(22-9-13-4-6-21-7-5-13)17(27)19-25-26-20(30-19)23-10-14-2-3-15-16(8-14)29-12-28-15/h2-8,11,22H,9-10,12H2,1H3,(H,23,26)
|
||||
InChIKey |
UQKIMTZGDDFLIL-UHFFFAOYSA-N
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
HIF-1 signaling pathway | |||||
Transcriptional misregulation in cancer | |||||
Rheumatoid arthritis | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
S1P3 pathway | |||||
VEGFR1 specific signals | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.